Details for Patent: 10,723,730

Which drugs does patent 10,723,730 protect, and when does it expire?

Patent 10,723,730 protects IBRANCE and is included in two NDAs.

Protection for IBRANCE has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has forty-eight patent family members in twenty-four countries.

Summary for Patent: 10,723,730

Title:	Solid forms of a selective CDK4/6 inhibitor
Abstract:	This invention relates to the crystalline free base of acetyl-8-cyclopentyl-5-methyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-8H-pyrido[2,3-d]pyrimidin-7-one, formula (1) having improved properties, to pharmaceutical compositions and dosage forms comprising the free base, and to methods for making and using such compounds, compositions and dosage forms in the treatment of cell proliferative diseases, such as cancer.
Inventor(s):	Brian Patrick Chekal, Nathan D. Ide
Assignee:	Pfizer Corp SRL
Application Number:	US15/808,577
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 10,723,730
Patent Claim Types: see list of patent claims	Composition; Compound;

Drugs Protected by US Patent 10,723,730

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Pfizer	IBRANCE	palbociclib	CAPSULE;ORAL	207103-001	Feb 3, 2015		RX	Yes	No					Y
Pfizer	IBRANCE	palbociclib	CAPSULE;ORAL	207103-002	Feb 3, 2015		RX	Yes	No					Y
Pfizer	IBRANCE	palbociclib	CAPSULE;ORAL	207103-003	Feb 3, 2015		RX	Yes	Yes					Y
Pfizer	IBRANCE	palbociclib	TABLET;ORAL	212436-001	Nov 1, 2019		RX	Yes	No					Y

International Family Members for US Patent 10,723,730

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Argentina	094842
Australia	2014220354
Brazil	112015019508
Canada	2900322